Crystalline form of sofpironium bromide and preparation method thereof
AssigneeBotanix SB, Inc.
InventorsKazuyoshi Marubayashi, Masahito Watanabe, Herbert R. Brinkman
Life of this patent
Estimating the term…
Abstract
A cocrystal containing the 1′R-diastereomer and the 1′S-diastereomer of sofpironium bromide at a ratio of 1:3 (Form CO), a crystal mixture (for example, Form B) containing Form CO and a crystalline form of the 1′R-diastereomer (Form MN), and a method for preparing sofpironium bromide, which is suitable for manufacture of the crystal mixture are provided. Form CO and a crystalline form of sofpironium bromide containing Form CO (for example, Form B) have superior stability without hygroscopic property, and accordingly they can be preferably used as a raw material of medicaments.
Claims10
Sofpironium bromide crystal Form B characterized by showing peaks at 5.9±0.2, 7.2±0.2, 7.7±0.2, 11.1±0.2, 22.3±0.2, and 24.6±0.2 as diffraction angles 2θ in a powder X-ray diffraction spectrum, wherein Form B is a mixture of
- a) sofpironium bromide cocrystal Form CO, and
- b) sofpironium bromide crystal Form MN,
- wherein said cocrystal Form CO comprises, in a 1:3 ratio:
- a compound shown as formula I-a
- and
- a compound shown as formula I-b
- wherein the cocrystal Form CO has a purity of not less than 98% w/w based on the content of the compound (I), represented by the formula (I)
- said cocrystal Form CO being characterized by showing peaks at 5.9±0.2, 7.6±0.2, 11.0±0.2, and 22.2±0.2 degrees as diffraction angles 2θ in a powder X-ray diffraction spectrum and has a single sharp endothermic peak value of 150° C. using a thermal analysis method as described in Japanese Pharmacopoeia (17th Edition);
- and
- wherein said sofpironium bromide crystal Form MN, which is a single crystal form of formula I-a, is characterized by showing peaks at 7.1±0.1, 21.4±0.1, 22.3±0.1, and 24.5±0.1 as diffraction angles 2θ in a powder X-ray diffraction spectrum.
Dependencies are inferred from the claim text.